HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1

Q3 2024 13F Holders as of 30 Sep 2024

Type / Class
Debt / NOTE 1.000% 8/1
Unit price / market price
$1.19
Total 13F principal
$680,559,400
Principal change
+$86,839,000
Total reported value
$810,707,471
Number of holders
75
Value change
+$105,250,543
Number of buys
31
Number of sells
30

Institutional Holders of HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 as of Q3 2024

As of 30 Sep 2024 HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 had 75 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions held a total of $680,559,400 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included CAMDEN ASSET MANAGEMENT L P /CA, MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, MACKAY SHIELDS LLC, LAZARD ASSET MANAGEMENT LLC, Calamos Advisors LLC, Polar Asset Management Partners Inc., WOLVERINE ASSET MANAGEMENT LLC, Voya Investment Management LLC, and Jefferies Financial Group Inc..
This table shows 75 bond principal holders of the security as of 30 Sep 2024.
Investor Option Weight % Change % Value $ * Price $ Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.